Search clinical trials for: Antipsychotic/Risperidone Consta

Total 2944 results

Janssen, LP

Completed

Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA) (SOURCE)

Schizophrenia

United States
Duke University
Janssen, LP

Terminated

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

Schizophrenia

United States
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Schizophrenia

United States
Northwestern University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

Schizophrenia | Schizoaffective Disorder

United States
Zogenix, Inc.

Completed

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Réseau de Santé Vitalité Health Network
Janssen Inc.

Unknown

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Schizophrenia Spectrum and Other Psychotic Disorders

Canada
The University of Texas Health Science Center at...
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center

Schizophrenia | Schizoaffective

United States
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder

Schizophrenia

Korea, Republic of
Janssen Cilag N.V./S.A.

Completed

A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode

Schizophrenia

South Africa
Dartmouth-Hitchcock Medical Center
Janssen, LP

Completed

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

Psychotic Disorders | Schizophrenia | Substance Abuse | Alcohol Abuse

United States
Duke University
Janssen, LP

Completed

Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence

Schizophrenia | Schizoaffective Disorder

United States
Janssen-Cilag Ltd.

Completed

Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia

Schizophrenia

Brazil
Vanderbilt University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder? (Consta)

Bipolar Disorder

United States
Northwell Health
National Alliance for Research on Schizophrenia and Depression; The Zucker...

Terminated

Optimizing Response in Psychosis Study (ORP)

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Psychotic Disorder Not Otherwise Specified

United States
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

Schizophrenia

United States
University of Pittsburgh
Janssen Pharmaceuticals

Completed

Risperdal Consta for Bipolar Disorder

Bipolar I Disorder

United States
Janssen Pharmaceutica N.V., Belgium

Completed

Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

Schizophrenia

United Kingdom, Slovenia, Denmark, Finland, France, Greece, Israel, Norway, Sweden, Switzerland
Johnson & Johnson Taiwan Ltd

Completed

An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment

Schizophrenia | Schizoaffective Disorders
Emory University
Janssen, L.P. - Investigator Initiated Studies Program

Completed

Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Janssen Korea, Ltd., Korea

Completed

A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)

Mental Disorders | Schizophrenia | Tranquilizing Agents | Therapeutic Uses | Physiological Effects of Drugs | Psychotropic Drugs | Antipsychotic Agents
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.

Bipolar Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

Bipolar Disorder

United States, Ukraine, Taiwan, Spain, Poland, India, Malaysia, Russian Federation, Slovakia, Austria
Luye Pharma Group Ltd.

Completed

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
Luye Pharma Group Ltd.

Completed

Bioavailability of LY03004 and Risperdal® Consta®

Schizophrenia | Schizoaffective Disorder

United States
University of Illinois at Chicago
Weill Medical College of Cornell University; Janssen, LP

Completed

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Janssen-Cilag International NV

Completed

InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

Schizophrenia

France, Germany, Spain, South Africa, Turkey, Greece, Czech Republic, Russian Federation
Xian-Janssen Pharmaceutical Ltd.

Terminated

An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

Schizophrenia
Rovi Pharmaceuticals Laboratories

Completed

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia (PRISMA-3)

Acute Schizophrenia

United States, Ukraine
US Department of Veterans Affairs

Completed

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Rovi Pharmaceuticals Laboratories

Completed

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (PRISMA-1)

Schizophrenia | Schizoaffective Disorder

Spain, South Africa, Russian Federation, Croatia
Zogenix, Inc.

Completed

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

Schizophrenia

United States
Lone Baandrup
University of Copenhagen; Glostrup University Hospital, Copenhagen; Danish Center... and other collaborators

Recruiting

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

Dual Diagnosis

Denmark
University of Alabama at Birmingham

Withdrawn

Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression

Depression | Impulsivity | Active Suicidal Ideation

United States
Janssen-Cilag S.p.A.

Completed

Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Hoffmann-La Roche

Completed

A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers

Healthy Volunteer

France
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Schizophrenia

United States, Ukraine, Germany, Spain, India, Russian Federation, Czech Republic, Austria, Hungary, Lithuania, Bulgaria, Estonia, Poland, France
Janssen-Ortho Inc., Canada

Terminated

A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

Schizophrenia

Canada, United Kingdom, Australia, Ireland
Rovi Pharmaceuticals Laboratories

Completed

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension (PRISMA-3_OLE)

Schizophrenia

United States, Ukraine
Changhua Christian Hospital

Terminated

Risperidone and Zotepine in the Treatment of Delirium

Delirium

Taiwan
Xijing Hospital

Unknown

Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients (rTMSfMRI)

Schizophrenia

China
Janssen-Ortho Inc., Canada

Completed

A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder

Canada
Hospital Psiquiatrico Infantil Dr. Juan N. Navarro...

Completed

Guideline vs Usual Treatment in Schizophrenic Adolescents (ACER)

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

Autistic Disorder | Autism

United States
Janssen Scientific Affairs, LLC

Completed

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Schizophrenia | Bipolar Disorder

United States
Rovi Pharmaceuticals Laboratories

Recruiting

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (QUARTZ)

Schizophrenia

Jordan
Xian-Janssen Pharmaceutical Ltd.

Withdrawn

Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants

Healthy

China
VA Office of Research and Development
University of Colorado, Denver

Withdrawn

Nicotinic Receptors and Schizophrenia

Schizophrenia

United States
Janssen-Cilag Ltd.

Completed

A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children

Child Behavior Disorders | Learning Disorders
Janssen, LP

Completed

A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.

Schizophrenia | Schizoaffective Disorder
Janssen Pharmaceutical K.K.

Completed

A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia

Schizophrenia

Search clinical trials for: Antipsychotic/Risperidone Consta

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations